BioMarin Pharmaceutical Inc. Q2 FY2026 earnings call

• Acquisition and Integration of Amicus

  • The acquisition of Amicus closed in April 2026 and integration is proceeding faster than initially planned, with deleveraging expected to occur approximately one year earlier than originally communicated.
  • Total peak revenue potential for the combined Amicus assets (Gallifold + Pombility and Opfolda) is projected at $2.6 billion by the mid-2030s, with $1.4 billion peak revenue for Gallifold and $1.2 billion peak revenue for Pombility and Opfolda.
  • Annual cost synergies are expected to reach $220 million, fully realized by 2028, representing a 50% reduction from Amicus's 2025 non-GAAP operating expenses. Over 70% of synergies will come from G&A, with the remainder from R&D.
  • The acquired Amicus assets are expected to reach over 60% non-GAAP operating margin by 2030, and the acquisition will drive substantial non-GAAP diluted EPS accretion beginning in 2027, alongside higher operating cash flow.

• Commercial Highlights

  • Voxogo maintained 90% patient retention in the U.S. following the February 2026 launch of a competitor product, demonstrating strong physician and patient confidence in Voxogo's extensive evidence base. BioMarin remains the only company with approval to treat patients under 2 years old globally.
  • BioMarin recently received European approval for a label expansion of Palinteq to include adolescents ages 12+ with PKU, with a strong early launch in the U.S. for this population.
  • Gallifold is already approved in 40 countries, and BioMarin plans to expand into over 10 additional markets; Pombility and Opfolda are planned for expansion into over 20 additional new markets. Growth will be driven by expanded diagnosis initiatives (AI patient identification, genetic testing, newborn screening, family cascade screening) and increased provider/patient awareness.

• Research and Development Highlights

  • BioMarin completed and submitted a supplemental New Drug Application (sNDA) for Voxogo to treat hypochondriplasia, cutting the time from database lock to submission to 79 days (top quartile industry benchmark) enabled by AI and parallel processing. Full Phase 3 data will be presented as a late-breaking presentation in September 2026, with a potential launch in 2027.
  • BMN820 (formerly DMX200), a late-stage oral CCR2 inhibitor acquired from Amicus, is in Phase 3 development for focal segmental glomerulosclerosis (FSGS). Phase 3 data is expected in 2028, and the asset has the potential to treat a broad FSGS patient population with an unmet medical need. BioMarin holds exclusive U.S. commercial rights, with Dimerix leading trial operations.
  • BMN333, BioMarin's next-generation achondroplasia candidate, is in a seamless Phase 2/3 trial with enrollment ongoing, and top-line data is expected in 2027.

Total Q2 2026 revenue reached nearly $1 billion, a 20% year-over-year increase.

1. Metabolic Conditions Business Unit: Total Q2 revenue was $695 million, representing 25% year-over-year growth, contributing 69.5% of total Q2 revenue. Included in this segment: Gallifold grew pro forma 10% year-over-year; Pombility and Opfolda grew pro forma over 65% year-over-year; LNZIC grew 27% year-over-year; Vemism faced a quarterly headwind from order timing after a strong Q1; Naglazyme saw a slight tailwind from order timing ahead of an expected lighter Q3.
2. Skeletal Conditions (Voxogo): Voxogo delivered 14% year-over-year revenue growth in Q2, contributing approximately 14% of total Q2 revenue. The company remains on track to make Voxogo BioMarin's first $1 billion annual product.

• Management raised full-year 2026 guidance for total revenue, Voxogo revenue, and non-GAAP diluted earnings per share, reflecting stronger than expected first-half performance. Voxogo full-year revenue is now guided to a minimum of $1 billion, hitting blockbuster status.
• Q3 2026 revenue is expected to be slightly higher than Q2 2026, reflecting a full quarter of Amicus asset contributions. Q3 non-GAAP diluted EPS is expected to be slightly higher than Q2 2026.
• Q4 2026 is expected to be the strongest quarter of the year, with revenue representing well over 50% of total second-half 2026 revenue driven by typical ordering dynamics in select markets. Q4 non-GAAP diluted EPS is expected to be significantly higher than Q3 2026, representing the highest quarterly EPS of the year, as cost synergy benefits begin to meaningfully materialize.
• Approximately 50% to slightly more than 50% of the $220 million total annual cost synergies from the Amicus acquisition are expected to be realized in 2027, with full synergies realized in 2028.

• The ITC patent case against BioMarin's competitor has an initial ALJ determination scheduled for August 21, 2026, with a final Commission decision expected in December 2026 and a presidential review period extending into early 2027. Post-ITC process, BioMarin plans to enforce its patents in federal district court, but there is uncertainty around the final outcome of the case and any potential exclusion orders.
• Continued competitive entry into the achondroplasia market could lead to additional patient switching from Voxogo and pressure on new patient acquisition, potentially impacting Voxogo's long-term revenue trajectory.
• Development of pipeline assets (including BMN820, BMN333, and Voxogo's hypochondriplasia indication) carries inherent clinical and regulatory risk, and positive clinical data is not guaranteed.
• Integration of the Amicus business may take longer than expected, and cost synergies may not reach the targeted $220 million annual run rate by 2028.

Q: What is the timeline for achieving full Amicus synergy targets, and why is deleveraging being pulled forward? What is the competitive dynamic for Voxogo new patients after the competitor's launch? / A: Most synergy decisions are already complete, and integration is progressing ahead of plan. The acquisition is still expected to be modestly dilutive (near break-even) in 2026, accretive in 2027, with 50%+ of total synergies realized in 2027 and full synergies realized in 2028. Only ~10% of existing Voxogo patients have switched to the competitor; the competitor's total enrollment figure includes both new and switched patients. Voxogo retains exclusive approval for patients under 2, who make up the majority of new patient starts, supporting raised full-year Voxogo guidance above $1 billion. Competitive launch pace has been slower than expected due to the fragmented U.S. achondroplasia market.

Q: Will Amicus cost synergies fall to the bottom line or be reinvested? What is BioMarin's appetite for future business development, and what types of assets will it target? / A: Most synergies will fall to the bottom line, with a modest portion reinvested to accelerate growth of the acquired Amicus assets. Following the Amicus acquisition, BioMarin is now a more diversified company with a strong growing commercial portfolio, and its primary BD focus is expanding its clinical-stage pipeline over the next 12-18 months. BioMarin will prioritize assets in genetic rare diseases that leverage its existing commercial, regulatory, and manufacturing capabilities, similar to the Amicus acquisition.

Q: Why has diagnosis of late-onset and female Fabry disease (for Gallifold) been slow historically, and what will BioMarin do differently? What is the timeline for the upcoming ITC patent decision? / A: Fabry disease is highly heterogeneous, with symptoms affecting multiple organ systems and patients seeing a wide range of providers, leading to an average 7-10 year diagnostic delay, which has held back historical diagnosis rates. BioMarin will leverage its decades of rare disease diagnostic experience to scale initiatives including electronic health record flagging, provider education, and family cascade screening to identify undiagnosed patients faster. For the ITC case, an initial administrative law judge ruling is due August 21, 2026, with a final Commission decision expected December 21, 2026, and presidential review running through February 2027. BioMarin will pursue patent enforcement in federal court after the ITC process concludes.

Q: What characteristics do switching Voxogo patients have, and how will the ex-U.S. competitive dynamic differ from the U.S. once competitors launch there? / A: Most switching patients cite injection fatigue and preference for weekly dosing as their primary reason for switching. The 90% of retained patients stay due to Voxogo's long-standing, robust efficacy and safety evidence base, and the strong trusted patient support relationships BioMarin has built with families. No competitors have launched ex-U.S. yet, but the competitive dynamic is not expected to be drastically different from the U.S. BioMarin will continue to monitor switching trends closely and does not plan to disclose forward-looking switching projections at this time. The 10% switching observed to date is already baked into 2026 guidance.